Thomas Steyer’s Farallon Capital is Buying These 5 Stocks

3. United Therapeutics Corporation (NASDAQ:UTHR)

Number of Hedge Fund Holders: 46

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology firm that researches and develops therapeutics for chronic and life threatening diseases in the United States and internationally. Thomas Steyer’s fund added United Therapeutics Corporation (NASDAQ:UTHR) to its Q4 portfolio by buying 320,760 shares worth $69.3 million, representing 0.36% of the total 13F holdings. 

In 2021, United Therapeutics Corporation (NASDAQ:UTHR) reported a full-year revenue of $1.68 billion, an increase of 13.63% compared to the prior year. However, the company’s net income shrank from $514.8 million in 2020 to $475.8 million in 2021. 

Wedbush analyst Liana Moussatos on February 28 reiterated an Outperform rating on United Therapeutics Corporation (NASDAQ:UTHR) but lowered the firm’s price target on the shares to $236 from $276. 

According to Insider Monkey’s database of 924 elite hedge funds, United Therapeutics Corporation (NASDAQ:UTHR) was found in the public stock portfolios of 46 hedge funds. They collectively held stakes in the company worth $2.6 billion. Kurt Von Emster’s VenBio Select Advisor is the biggest position holder in United Therapeutics Corporation (NASDAQ:UTHR), with more than 3 million shares valued at $655.8 million.